MedTrace Logo

The Efficacy, Safety And Toleration Of CP-866,087 In Pre-Menopausal Women With Female Sexual Arousal Disorder.

NCT00482664 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 84

Last updated 2010-11-01

No results posted yet for this study

Summary

CP-866,087 is a non-hormonal compound, acting on the central nervous system, which has been shown in animal models to restore sexual function.

Conditions

  • Sexual Dysfunction, Physiological

Interventions

DRUG

CP-866,087

Tablets for oral administration

DRUG

CP-866,087

Tablets for oral administration

DRUG

CP-866,087

Tablets for oral administration

DRUG

Placebo

Tablets for oral administration

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-07-31
Primary Completion
2008-09-30
Completion
2008-10-31

Countries

  • Australia
  • Denmark
  • Norway
  • South Africa
  • Sweden

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00482664 on ClinicalTrials.gov